Infusion of autograft natural killer cell/CD14 + HLA-DR DIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation

A. Kansagra, D. J. Inwards, S. M. Ansell, I. N. Micallef, P. B. Johnston, W. J. Hogan, S. N. Markovic, L. F. Porrata

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14 + HLA-DR DIM cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14 + HLA-DR DIM ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14 + HLA-DR DIM. With a median follow-up of 57.2 months (range: 2.1-84.6 months), patients with an A-NKC/A-CD14 + HLA-DR DIM ratio of < 3/40.29 experienced superior OS (5-year OS rates of 84% (95% confidence interval (CI), 72-91%) vs 48% (95% CI, 34-62%), P<0.0002, respectively) and PFS (5-year PFS rates of 59% (95% CI, 47-71%) vs 32% (95% CI, 20-48%), P<0.002, respectively). Multivariate analysis revealed that A-NKC/A-CD14 + HLA-DR DIM ratio was an independent predictor for PFS (hazard ratio (HR)=0.56, 95% CI, 0.32-0.96, P<0.03) and OS (HR=0.34, 95% CI, 0.16-0.68, P<0.002). The A-NKC/A-CD14 + HLA-DR DIM ratio provides a platform to target specific autograft immune effector cells to improve clinical outcomes in NHL patients undergoing APBHSCT.

Original languageEnglish (US)
Pages (from-to)146-154
Number of pages9
JournalBone Marrow Transplantation
Volume53
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this